Biotech Values

[tinkershaw]

http://www.medicalnewstoday.com/articles/169171.php

To my knowledge it has only been compared to exantide BID, not exanitide LAR. The quick look I did only said it did better than BID, but no numbers or details were given.

Again, not unexpected at all. The future is 1x a week, i.e, exanitide LAR, so that is where the real comparisons will be made. Byetta bid is a good drug, but it is being improved upon.

So the answer is there are no such comparisons that I know of, and I have not seen any numbers to support the conclusions given by Roche for Taspoglutide. I would assume if the numbers were ground breaking the top line numbers at least would have been provided. Maybe they were in a more detailed press release, but I don't have the time to look it up at present if that is the case.

Tinker